Zhejiang Garden Biopharmaceutical Co.,Ltd. (SHE:300401)
China · Delayed Price · Currency is CNY 15.58
+1.11 (7.67%)
Aug 20, 2026, 3:04 PM CST
SHE:300401 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 8,471 | 8,217 | 7,967 | 6,486 | 7,929 | 7,813 | |
Market Cap Growth | -0.02% | 3.14% | 22.84% | -18.20% | 1.48% | -9.56% |
Enterprise Value | 8,941 | 8,453 | 8,285 | 6,437 | 7,902 | 6,922 |
Last Close Price | 15.58 | 14.99 | 14.42 | 11.55 | 13.92 | 13.71 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 33.74 | 26.95 | 25.77 | 33.72 | 20.66 | 16.15 |
Forward PE | 19.48 | 16.00 | 18.18 | 9.98 | 12.09 | 15.59 |
PS Ratio | 6.55 | 6.64 | 6.41 | 5.93 | 5.59 | 6.99 |
PB Ratio | 2.37 | 2.36 | 2.48 | 2.24 | 3.08 | 3.42 |
P/TBV Ratio | 2.53 | 2.51 | 2.63 | 2.38 | 3.30 | 3.69 |
P/FCF Ratio | 78.13 | 72.86 | - | - | - | - |
P/OCF Ratio | 21.47 | 17.31 | 17.08 | 40.54 | 21.03 | 15.25 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.91 | 6.83 | 6.66 | 5.88 | 5.58 | 6.20 |
EV/EBITDA Ratio | 16.97 | 15.69 | 17.57 | 21.26 | 17.24 | 14.12 |
EV/EBIT Ratio | 26.03 | 23.44 | 26.23 | 37.98 | 19.88 | 15.53 |
EV/FCF Ratio | 82.47 | 74.95 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.51 | 0.50 | 0.53 | 0.55 | 0.21 | 0.18 |
Debt / EBITDA Ratio | 3.49 | 3.25 | 3.64 | 5.24 | 1.16 | 0.85 |
Debt / FCF Ratio | 16.96 | 15.51 | - | - | - | - |
Net Debt / Equity Ratio | 0.13 | 0.12 | 0.09 | 0.03 | -0.01 | -0.04 |
Net Debt / EBITDA Ratio | 0.89 | 0.77 | 0.62 | 0.28 | -0.05 | -0.18 |
Net Debt / FCF Ratio | 4.34 | 3.69 | -20.79 | -0.99 | 7.80 | 0.43 |
Asset Turnover | 0.22 | 0.22 | 0.23 | 0.23 | 0.37 | 0.32 |
Inventory Turnover | 0.87 | 0.70 | 0.64 | 0.67 | 1.00 | 0.94 |
Quick Ratio | 1.42 | 1.65 | 1.24 | 1.26 | 0.55 | 0.66 |
Current Ratio | 2.18 | 2.52 | 1.94 | 1.95 | 1.06 | 1.24 |
Return on Equity (ROE) | 7.95% | 9.09% | 10.12% | 7.04% | 15.81% | 19.91% |
Return on Assets (ROA) | 3.70% | 3.96% | 3.63% | 2.26% | 6.49% | 7.85% |
Return on Invested Capital (ROIC) | 7.78% | 8.41% | 8.40% | 5.59% | 14.53% | 19.66% |
Return on Capital Employed (ROCE) | 7.20% | 7.50% | 7.30% | 4.20% | 14.10% | 16.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.25% | 3.71% | 3.88% | 2.97% | 4.84% | 6.19% |
FCF Yield | 1.28% | 1.37% | -0.18% | -1.30% | -0.04% | -2.60% |
Dividend Yield | 0.78% | 0.75% | 0.79% | 0.61% | 1.01% | 1.37% |
Payout Ratio | 35.66% | 30.23% | 21.80% | 53.59% | 31.99% | 13.64% |
Buyback Yield / Dilution | -3.82% | -0.53% | 1.07% | -9.65% | -0.85% | -7.38% |
Total Shareholder Return | -3.09% | 0.23% | 1.86% | -9.04% | 0.16% | -6.01% |